Dr. Blumenfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6010 Hidden Valley Rd Ste 200
Suite 2
Carlsbad, CA 92011Phone+1 760-631-3000Fax+1 760-631-3016
Education & Training
- UMass Chan Medical SchoolResidency, Neurology, 1986 - 1990
- University of the WitwatersrandClass of 1981
Certifications & Licensure
- CA State Medical License 1989 - 2025
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Publications & Presentations
PubMed
- Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Re...Andrew M Blumenfeld, Laszlo Mechtler, Lisa Cook, Christopher Rhyne, Brian Jenkins
Pain and Therapy. 2024-12-01 - Cerebral Artery Vasoconstriction After Galcanezumab Loading Dose for Migraine Prevention: A Case Report.Thanin Asawavichienjinda, Nutchawan Jittapiromsak, Andrew Blumenfeld
Pain and Therapy. 2024-12-01 - Healthcare resource use and costs associated with the misdiagnosis of migraine.Jae Rok Kim, Tae Jin Park, Maria Agapova, Andrew Blumenfeld, Jonathan H Smith
Headache. 2024-08-28
Lectures
- InjectionED: Advanced Injection Training for Pain Disorders of the Head, Neck & FaceCvent Online Event Registration Software, San Diego, California - 12/1/2012
- Headaches: Easing the PainScripps Conference Services & CME /Scripps Translational Science Institute (STSI), La Jolla, Califor - 2/18/2012
Press Mentions
- Treating Chronic Migraine: One Woman’s Path to Managing the DiseaseMarch 9th, 2023
- Theranica's Nerivio® Cleared by FDA for Preventive Treatment of MigraineFebruary 28th, 2023
- Teva Announces New Analysis of Consistency in Migraine Days over the Course of a Dosing Regimen for AJOVY® (Fremanezumab-Vfrm) Injection Published in HeadacheOctober 7th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: